Bionyra Pharma launched from stealth after raising an oversubscribed $165 million Series A to develop next-generation biologics for severe immunological and inflammatory diseases. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Sanofi Ventures, Arkin Bio, and others. The clinical-stage company is led by co-founder and CEO Frédéric Marrache, MD, PhD, who previously worked on immune-mediated drug development at Sanofi and described the unmet need framing that guided target and pathway selection. Board seats are set to include multiple investors tied to the financing. The size and oversubscription of the round signal investor appetite for differentiated biologics platforms in inflammation, particularly when companies can articulate target selection and modality differentiation early.